Dashboard
Manage Tickers

ATHAAthira Pharma, Inc.

Nasdaq athira.com


$ 0.49 $ -0.02 (-3.99 %)    

Tuesday, 17-Sep-2024 15:58:34 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 0.4858
$ 0.54
$ 0.49 x 300
$ 0.49 x 500
$ 0.49 - $ 0.54
$ 0.46 - $ 4.30
1,142,679
na
18.67M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

athira-pharma-to-focus-on-advancement-of-ath-1105-for-the-treatment-of-neurodegenerative-diseases-includes-a-reduction-in-workforce-of-70-athira-expects-one-time-costs-of-28m-and-cost-savings-of-134m-on-an-annualized-basis
Athira Pharma To Focus On Advancement Of A...
09/17/2024 13:02:14

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical tria...

crude-oil-down-1-dollar-tree-shares-tumble-after-downbeat-earnings
Crude Oil Down 1%; Dollar Tree Shares Tumb...
09/04/2024 17:32:14

jmp-securities-downgrades-athira-pharma-to-market-perform
JMP Securities Downgrades Athira Pharma to...
09/04/2024 16:13:18

JMP Securities analyst Jason Butler downgrades Athira Pharma (NASDAQ:ATHA) from Market Outperform to Market Perform.

btig-downgrades-athira-pharma-to-neutral
BTIG Downgrades Athira Pharma to Neutral
09/04/2024 14:36:58

BTIG analyst Thomas Shrader downgrades Athira Pharma (NASDAQ:ATHA) from Buy to Neutral.

us-stocks-mixed-trade-gap-widens-in-july
US Stocks Mixed; Trade Gap Widens In July
09/04/2024 14:06:06

athira-pharmas-alzheimers-candidate-fails-to-improve-cognition-and-function-in-patients-with-mildmoderate-disease-stock-sinks
Athira Pharma's Alzheimer's Candidate Fail...
09/04/2024 12:48:35

Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's tr...

why-gitlab-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket
Why GitLab Shares Are Trading Higher By Ar...
09/04/2024 10:39:51

athira-pharma-shares-resume-trade
Athira Pharma Shares Resume Trade
09/03/2024 20:30:59

trading-halt-halt-status-updated-at-42500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 4:25:...
09/03/2024 20:25:05

athira-reports-results-from-phase-23-lift-ad-clinical-trial-of-fosgonimeton-for-mild-to-moderate-alzheimers-disease-lift-ad-trial-did-not-meet-primary-endpoint-of-gst-and-key-secondary-endpoints-of-cognition-and-function
Athira Reports Results From Phase 2/3 LIFT...
09/03/2024 20:02:38

trading-halt-halted-at-40011-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:00:11 p.m. ET - ...
09/03/2024 20:00:21

rodman--renshaw-initiates-coverage-on-athira-pharma-with-buy-rating-announces-price-target-of-22
Rodman & Renshaw Initiates Coverage On Ath...
08/19/2024 14:37:25

Rodman & Renshaw analyst Elemer Piros initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces ...

athira-pharma-q2-eps-070-beats-074-estimate
Athira Pharma Q2 EPS $(0.70) Beats $(0.74)...
08/01/2024 20:48:16

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.74)...

athira-pharma-to-present-preclinical-data-demonstrating-new-insights-into-the-mechanism-by-which-fosgonimeton-protects-neurons-from-alzheimers-disease-related-pathology-at-aaic-2024
Athira Pharma To Present Preclinical Data ...
07/31/2024 12:28:34

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms t...

jmp-securities-reiterates-market-outperform-on-athira-pharma-maintains-19-price-target
JMP Securities Reiterates Market Outperfor...
06/20/2024 14:59:49

JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...

athira-pharma-advances-als-drug-with-successful-phase-1-trial-in-healthy-volunteers
Athira Pharma Advances ALS Drug with Succe...
06/11/2024 11:03:32

BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical co...

athira-pharma-to-be-issued-us-patent-for-methods-of-treating-parkinsons-disease-and-lewy-body-disease
Athira Pharma To Be Issued US Patent For "...
06/03/2024 19:34:42

jmp-securities-reiterates-market-outperform-on-athira-pharma-maintains-19-price-target
JMP Securities Reiterates Market Outperfor...
05/16/2024 16:53:32

JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...

athira-pharma-q1-2024-gaap-eps-069-beats-078-estimate
Athira Pharma Q1 2024 GAAP EPS $(0.69) Bea...
05/15/2024 20:40:48

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.78)...

athira-pharma-announces-publication-of-preclinical-data-highlighting-fosgonimeton-treatment-in-models-of-alzheimers-disease
Athira Pharma Announces Publication of Pre...
04/11/2024 11:09:42

Key findings reported in the study publication regarding fosgonimeton in preclinical models of Alzheimer's disease include:...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION